Literature DB >> 27591084

Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality.

Hicham I Cheikh Hassan1, Mila Tang2, Ognjenka Djurdjev2, David Langsford1, Manish M Sood3, Adeera Levin4.   

Abstract

The risk of infection in advanced chronic kidney disease (CKD) and its subsequent impact on adverse outcomes are not well established. Therefore, we determined the association of an infectious episode with the subsequent risk of cardiovascular ischemia, congestive heart failure, end-stage kidney disease or mortality in a Canadian prospective cohort (CanPREDDICT) of patients with advanced CKD (eGFR: 15-45 ml/min/1.73m(2)) followed by nephrologists for up to 5 years. Infectious episodes were classified by anatomic location and identified by positive culture, hospital admission, or use of antibiotics. Competing risk models were used to examine the time-varying risk of infection and the risk of cardiovascular ischemia, congestive heart failure, or end-stage kidney disease accounting for the competing risk of mortality. All outcomes were independently adjudicated. Of 2370 patients (mean age, 68 years; mean baseline eGFR, 28.2 mL/min/1.73m(2)), 575 patients (24.3%) had recorded infections; 378 had 1 infection episode, whereas 197 had 2 or more episodes, the most common being urinary and respiratory. An infectious episode was independently associated with an increased risk of cardiovascular ischemia (hazard ratio 1.80, 95% confidence interval 1.24-2.60), congestive heart failure (hazard ratio, 3.2; confidence interval, 2.25-4.61), end-stage kidney disease (hazard ratio, 1.58; confidence interval, 1.22-2.05) or mortality (hazard ratio, 3.39; confidence interval, 2.65-4.33). Thus, there is a high risk of infection in advanced CKD being associated with subsequent adverse outcomes.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac ischemia; chronic kidney disease; competing risks infection; congestive heart failure; dialysis; mortality

Mesh:

Year:  2016        PMID: 27591084     DOI: 10.1016/j.kint.2016.07.013

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  27 in total

1.  MicroRNA-34a Promotes Renal Fibrosis by Downregulation of Klotho in Tubular Epithelial Cells.

Authors:  Yong Liu; Xianjin Bi; Jiachuan Xiong; Wenhao Han; Tangli Xiao; Xinli Xu; Ke Yang; Chi Liu; Wei Jiang; Ting He; Yanlin Yu; Yan Li; Jingbo Zhang; Bo Zhang; Jinghong Zhao
Journal:  Mol Ther       Date:  2019-02-15       Impact factor: 11.454

2.  eGFR and the Risk of Community-Acquired Infections.

Authors:  Hong Xu; Alessandro Gasparini; Junichi Ishigami; Khaled Mzayen; Guobin Su; Peter Barany; Johan Ärnlöv; Bengt Lindholm; Carl Gustaf Elinder; Kunihiro Matsushita; Juan Jesús Carrero
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-17       Impact factor: 8.237

3.  Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.

Authors:  Iain C Macdougall; Sunil Bhandari; Claire White; Stefan D Anker; Kenneth Farrington; Philip A Kalra; Patrick B Mark; John J V McMurray; Chante Reid; Michele Robertson; Charles R V Tomson; David C Wheeler; Christopher G Winearls; Ian Ford
Journal:  J Am Soc Nephrol       Date:  2020-04-06       Impact factor: 10.121

4.  A negative association between low-density lipoprotein cholesterol level and infection risk in elderly stage 5 chronic kidney disease patients.

Authors:  Ping Liu; Shuying Zhang; Lijuan Jiang; Jinhong Ma; Xiaonan Shao
Journal:  Clin Exp Nephrol       Date:  2021-09-14       Impact factor: 2.801

Review 5.  Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms.

Authors:  Stefanie Steiger; Jan Rossaint; Alexander Zarbock; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2021-12-14       Impact factor: 10.121

6.  Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD.

Authors:  Mohamad A Hamad; Hilda Allam; Ashna Sulaiman; Karumathil Murali; Hicham I Cheikh Hassan
Journal:  Kidney Int Rep       Date:  2021-03-03

7.  Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis.

Authors:  Vanessa Stadlbauer; Angela Horvath; Werner Ribitsch; Bianca Schmerböck; Gernot Schilcher; Sandra Lemesch; Philipp Stiegler; Alexander R Rosenkranz; Peter Fickert; Bettina Leber
Journal:  Sci Rep       Date:  2017-11-15       Impact factor: 4.379

8.  Dialysis timing may be deferred toward very late initiation: An observational study.

Authors:  Yun-Lun Chang; Jie-Sian Wang; Hung-Chieh Yeh; I-Wen Ting; Han-Chun Huang; Hsiu-Yin Chiang; Chiung-Tzu Hsiao; Pei-Lun Chu; Chin-Chi Kuo
Journal:  PLoS One       Date:  2020-05-13       Impact factor: 3.240

Review 9.  Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk.

Authors:  Tomas Ganz; George R Aronoff; Carlo A J M Gaillard; Lawrence T Goodnough; Iain C Macdougall; Gert Mayer; Graça Porto; Wolfgang C Winkelmayer; Jay B Wish
Journal:  Kidney Med       Date:  2020-03-27

10.  The Risk of Adverse Events in Patients With Polycystic Kidney Disease With Advanced Chronic Kidney Disease.

Authors:  Sonali de Chickera; Ayub Akbari; Adeera Levin; Mila Tang; Pierre Brown; Ognjenka Djurdev; Mohan Biyani; Edward G Clark; Manish M Sood
Journal:  Can J Kidney Health Dis       Date:  2018-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.